Table 1. Baseline characteristics.
| Variables | Total population | Propensity-Matched population | |||||
|---|---|---|---|---|---|---|---|
| Total (n = 1,006) | 1st generation (n = 557) | 2nd generation (n = 449) | P value | 1st generation (n = 437) | 2nd generation (n = 437) | P value | |
| Age (yrs) | 62.5 (± 11.2) | 62.3 (± 10.9) | 62.8 (± 11.6) | 0.48 | 62.4 (± 11.0) | 62.7 (± 11.7) | 0.61 |
| Male | 784 (77.9%) | 448 (80.4%) | 336 (74.8%) | 0.03 | 339 (77.6%) | 331 (75.7%) | 0.52 |
| Diabetes | 408 (40.6%) | 231 (41.5%) | 177 (39.4%) | 0.51 | 181 (41.4%) | 173 (39.6%) | 0.58 |
| Hypertension | 626 (62.2%) | 338 (60.7%) | 288 (64.1%) | 0.26 | 281 (64.3%) | 283 (64.8%) | 0.89 |
| Dyslipidemia | 452 (44.9%) | 231 (41.5%) | 221 (49.2%) | 0.01 | 197 (45.1%) | 212 (48.5%) | 0.31 |
| Current smoker | 313 (31.1%) | 171 (30.7%) | 142 (31.6%) | 0.75 | 138 (31.6%) | 138 (31.6%) | 1.00 |
| Chronic kidney disease | 59 (5.9%) | 28 (5.0%) | 31 (6.9%) | 0.21 | 25 (5.7%) | 30 (6.9%) | 0.49 |
| ACS | 299 (29.7%) | 150 (26.9%) | 149 (33.2%) | 0.03 | 130 (29.7%) | 139 (31.8%) | 0.51 |
| CVA | 32 (7.9%) | 7 (9.0%) | 25 (7.7%) | 0.70 | 30 (6.9%) | 26 (5.9%) | 0.58 |
| Previous PCI | 210 (20.9%) | 119 (21.4%) | 91 (20.3%) | 0.67 | 93 (21.3%) | 91 (20.8%) | 0.87 |
| LVEF (%) | 57.5 (± 12.2) | 57.5 (± 11.9) | 57.4 (± 12.4) | 0.862 | 57.9 (± 11.7) | 57.6 (± 12.4) | 0.65 |
| Discharge medication | |||||||
| Statins | 773 (76.8%) | 421 (75.6%) | 352 (78.4%) | 0.29 | 335 (76.7%) | 344 (78.7%) | 0.47 |
| Beta-blocker | 599 (59.5%) | 345 (61.9%) | 254 (56.6%) | 0.09 | 262 (60.0%) | 248 (56.8%) | 0.34 |
| ACE inhibitors or ARB | 608 (60.4%) | 340 (61.0%) | 268 (59.7%) | 0.66 | 263 (60.2%) | 260 (59.5%) | 0.84 |
Values are mean ± SD or n (%). ACE = angiotensin-converting enzyme; ACS = acute coronary syndrome; ARB = angiotensin receptor blocker; CVA = cerebrovascular accident; LVEF = left ventricular ejection fraction; PCI = percutaneous coronary intervention.